Australia's most trusted
source of pharma news
Posted 25 February 2026 AM
The TGA is seeking to recoup tens of millions of dollars from pharma companies in ARTG listing fees that it claims have been inappropriately reported as exempt.
The issue is with compliance to the Annual Charge Exemption Scheme, which allows pharmas to list a drug on the ARTG but not pay annual fees until it's actually launched on the market. The exemption is required to be supported with records proving the drug had zero dollars in turnover that year, but many claimed exemptions are remaining unverified.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.